Your browser doesn't support javascript.
loading
Engineering an inducible leukemia-associated fusion protein enables large-scale ex vivo production of functional human phagocytes.
Windisch, Roland; Soliman, Sarah; Hoffmann, Adrian; Chen-Wichmann, Linping; Danese, Anna; Vosberg, Sebastian; Bravo, Jimena; Lutz, Sebastian; Kellner, Christian; Fischer, Alexander; Gebhard, Claudia; Redondo Monte, Enric; Hartmann, Luise; Schneider, Stephanie; Beier, Fabian; Strobl, Carolin Dorothea; Weigert, Oliver; Peipp, Matthias; Schündeln, Michael; Stricker, Stefan H; Rehli, Michael; Bernhagen, Jürgen; Humpe, Andreas; Klump, Hannes; Brendel, Christian; Krause, Daniela S; Greif, Philipp A; Wichmann, Christian.
Afiliación
  • Windisch R; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
  • Soliman S; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
  • Hoffmann A; Vascular Biology, Institute for Stroke and Dementia Research, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
  • Chen-Wichmann L; Department of Anesthesiology, University Hospital, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
  • Danese A; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
  • Vosberg S; Biomedical Center, Department of Physiological Genomics, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
  • Bravo J; Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
  • Lutz S; German Cancer Consortium, Partner site Munich, Munich 81377, Germany.
  • Kellner C; German Cancer Research Center, Heidelberg 69120, Germany.
  • Fischer A; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz 8010, Austria.
  • Gebhard C; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main 60596, Germany.
  • Redondo Monte E; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
  • Hartmann L; Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
  • Schneider S; Department of Internal Medicine III, University Hospital Regensburg, Regensburg 93053, Germany.
  • Beier F; Leibniz Institute for Immunotherapy, Regensburg 93053, Germany.
  • Strobl CD; Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
  • Weigert O; German Cancer Consortium, Partner site Munich, Munich 81377, Germany.
  • Peipp M; German Cancer Research Center, Heidelberg 69120, Germany.
  • Schündeln M; Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
  • Stricker SH; German Cancer Consortium, Partner site Munich, Munich 81377, Germany.
  • Rehli M; German Cancer Research Center, Heidelberg 69120, Germany.
  • Bernhagen J; Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
  • Humpe A; Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
  • Klump H; Institute of Human Genetics, University Hospital, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
  • Brendel C; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty University Hospital Aachen, Rheinisch-Westfälische Technische Hochschule Aachen, Aachen 52074, Germany.
  • Krause DS; Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität München, Munich 81377, Germany.
  • Greif PA; German Cancer Consortium, Partner site Munich, Munich 81377, Germany.
  • Wichmann C; German Cancer Research Center, Heidelberg 69120, Germany.
Proc Natl Acad Sci U S A ; 121(25): e2312499121, 2024 Jun 18.
Article en En | MEDLINE | ID: mdl-38857395
ABSTRACT
Ex vivo expansion of human CD34+ hematopoietic stem and progenitor cells remains a challenge due to rapid differentiation after detachment from the bone marrow niche. In this study, we assessed the capacity of an inducible fusion protein to enable sustained ex vivo proliferation of hematopoietic precursors and their capacity to differentiate into functional phagocytes. We fused the coding sequences of an FK506-Binding Protein 12 (FKBP12)-derived destabilization domain (DD) to the myeloid/lymphoid lineage leukemia/eleven nineteen leukemia (MLL-ENL) fusion gene to generate the fusion protein DD-MLL-ENL and retrovirally expressed the protein switch in human CD34+ progenitors. Using Shield1, a chemical inhibitor of DD fusion protein degradation, we established large-scale and long-term expansion of late monocytic precursors. Upon Shield1 removal, the cells lost self-renewal capacity and spontaneously differentiated, even after 2.5 y of continuous ex vivo expansion. In the absence of Shield1, stimulation with IFN-γ, LPS, and GM-CSF triggered terminal differentiation. Gene expression analysis of the obtained phagocytes revealed marked similarity with naïve monocytes. In functional assays, the novel phagocytes migrated toward CCL2, attached to VCAM-1 under shear stress, produced reactive oxygen species, and engulfed bacterial particles, cellular particles, and apoptotic cells. Finally, we demonstrated Fcγ receptor recognition and phagocytosis of opsonized lymphoma cells in an antibody-dependent manner. Overall, we have established an engineered protein that, as a single factor, is useful for large-scale ex vivo production of human phagocytes. Such adjustable proteins have the potential to be applied as molecular tools to produce functional immune cells for experimental cell-based approaches.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fagocitos / Diferenciación Celular Límite: Humans Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2024 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fagocitos / Diferenciación Celular Límite: Humans Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2024 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos